Archive · 23 Sep 2026
Experimental non-hormonal endometriosis drug enters early safety testing
Endometriosis is a condition where tissue grows outside the uterus and can cause pain, bleeding and fertility problems.
ENDO-205 is a new experimental drug being tested for this condition.
Unlike many current treatments, it is not designed to change reproductive hormones.
The drug is meant to become active in the unusual acidic environment around endometriosis lesions.
It may then damage the abnormal cells.
The first study will mainly check whether the drug is safe and what dose people can take.
It will not show yet whether the drug reduces pain or treats endometriosis.
Much larger studies will be needed to see whether it helps patients and affects fertility.
It is far too early to know whether it can replace hormone treatment or surgery.
The United States Food and Drug Administration cleared ENDO-205 for a Phase 1 study in healthy premenopausal women.
ENDO-205 is designed to activate in the acidic environment of endometriosis lesions and destroy abnormal cells.
The first trial will assess safety, tolerability, drug processing and dosing, not whether it treats endometriosis.
Later trials must examine effects on lesions, pain, disease progression, fertility, ovarian function and pregnancy outcomes.
The drug could eventually complement or reduce hormonal treatment and surgery, but its availability and effectiveness remain unproven.
- Who
- The United States Food and Drug Administration, ENDO-205 researchers and developers, and premenopausal women who may participate in the Phase 1 study.
- What
- The FDA cleared an early human study of ENDO-205, an experimental non-hormonal peptide therapy for endometriosis.
- When
- The Phase 1 study is planned or beginning; later clinical testing would be required to assess effectiveness.
- Where
- The FDA clearance is in the United States; potential approval in India would require review by the Central Drugs Standard Control Organisation.
- Why
- The drug is being developed to target endometriosis lesions directly without suppressing reproductive hormones.
- Drug
- ENDO-205, a first-in-class experimental non-hormonal targeted peptide therapy.
- Current stage
- Phase 1 clinical study in healthy premenopausal women of reproductive age.
- Initial goals
- Assess safety, tolerability, how the body processes the drug and appropriate dosing.
- Proposed mechanism
- The peptide is intended to activate in the acidic environment associated with endometriosis lesions and trigger abnormal-cell destruction.
- Effectiveness
- Whether it reduces lesions, pain or disease progression has not yet been established.
- Fertility
- Effects on ovarian function, menstrual cycles, ovulation, fertility and pregnancy remain unknown.
- India availability
- Any future application in India would need to meet the applicable Central Drugs Standard Control Organisation requirements.